BioCentury
ARTICLE | Clinical News

Novartis' infigratinib leads to 25.4% ORR in urothelial carcinoma patients

July 13, 2018 6:57 PM UTC

Data from 67 patients with previously treated advanced urothelial carcinoma with fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333) alterations in an expansion cohort of an open-label, international Phase I trial showed that once-daily 125 mg oral infigratinib (BGJ398) from Novartis AG (NYSE:NVS; SIX:NOVN) led to an overall response rate (ORR) of 25.4%, including 17 confirmed complete or partial responses, plus 26 cases of stable disease. Median progression-free survival (PFS) was 3.75 months and median overall survival (OS) was 7.75 months. Data were published in Cancer Discovery...